Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer
Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab Versus Short-course Radiotherapy Plus Chemotherapy as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer
Dechang Diao
76 participants
Jun 24, 2026
INTERVENTIONAL
Conditions
Summary
Safety and efficacy of Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab versus Short-course Radiotherapy plus Chemotherapy as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer. Complete Response (CR) Rate of Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab versus Short-course Radiotherapy plus Chemotherapy as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Short-course radiotherapy → CAPOX regimen chemotherapy (6 cycles) → undergo surgery or watch-and-wait strategy.
Nodal-Region Sparing short-course radiotherapy → PD-1 monoclonal antibody and bevacizumab combined with CAPOX regimen chemotherapy (4 cycles) → PD-1 monoclonal antibody combined with CAPOX regimen chemotherapy (2 cycles) → undergo surgery or watch-and-wait strategy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07674732